Coya Therapeutics enters $30M at-the-market equity offering with Leerink Partners

Coya Therapeutics, Inc.

Sales Agreement with Leerink Partners allows up to $30M gross proceeds from common stock sales on Nasdaq.
Leerink receives 3.0% commission on gross proceeds; Company may sell at its discretion.
Offering under existing shelf registration; no minimum obligation to sell.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Coya Therapeutics, Inc. entered into Sales Agreement with Leerink Partners LLC valued at up to $30,000,000 (effective 2026-05-12).

Action: entry
Agreement: atm program
Counterparty: Leerink Partners LLC
Value: up to $30,000,000
Effective: 2026-05-12

Exact text from the filing

On May 12, 2026, Coya Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC, as sales agent (“Leerink Partners”), pursuant to which the Company may offer and sell, from time to time through or to Leerink Partners, shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), for aggregate gross proceeds of up to $30,000,000

View on SEC.gov

629 material agreements filed in the last 30 days. Browse all material agreements →

Coya Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-218282

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.